Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Molecules ; 24(22)2019 Nov 12.
Artículo en Inglés | MEDLINE | ID: mdl-31718083

RESUMEN

New 1,2,3-thiadiazole and 1,2,3-selenadiazole derivatives, (4-[4-((4-bromobenzyl)oxy)-phenyl]-1,2,3-thiadiazole (5a), 4-[4-((4-chlorobenzyl)oxy)-phenyl]-1,2,3-thiadiazole (5b)), (4-[4-((4-bromobenzyl)oxy)-phenyl]-1,2,3-selenadiazole (6a), and 4-[4-((4-chlorobenzyl)oxy)-phenyl]-1,2,3-selenadiazole (6b)), were prepared and screened in vitro for their antimicrobial activity against various pathogenic microbes. In addition, two compounds (5a and 6a) were examined for their in vivo genotoxicity using rats and an 8-hydroxy-2'-deoxyguanosine (8-OHdG) assay. Compounds 5a and 5b were found to be highly active against Gram-positive and Gram-negative bacteria. In addition, a significant inhibition of urinary 8-OHdG level (50.2%) was observed upon treatment of animals with 500 mg/kg body weight (b.w.) of compound 6a (p < 0.0001). However, compound 5a increased urinary 8-OHdG levels. The lethal dose (LD50) values for compounds 5a and 6a were determined by an up-and-down procedure (OECD 425; OECD 1998), which showed that these compounds are safe, since the LD50 was >5000 mg/kg b.w. Thus, the tested compounds might have the potential for use as antibiotics, since they have low genotoxicity and strong antimicrobial activity.


Asunto(s)
Antiinfecciosos/síntesis química , Antiinfecciosos/farmacología , Mutágenos/síntesis química , Mutágenos/farmacología , Tiadiazoles/síntesis química , Tiadiazoles/farmacología , Antiinfecciosos/química , Relación Dosis-Respuesta a Droga , Compuestos Heterocíclicos , Dosificación Letal Mediana , Pruebas de Sensibilidad Microbiana , Mutágenos/química , Tiadiazoles/química
2.
Molecules ; 24(18)2019 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-31487813

RESUMEN

Glyoxalase-I (Glo-I) enzyme was established to be a valid target for anticancer drug design. It performs the essential detoxification step of harmful byproducts, especially methylglyoxal. A robust computer-aided drug design approach was used to design and validate a series of compounds with selenium or sulfur based heterorings. A series of in-house multi-armed 1,2,3-selenadiazole and 1,2,3-thiadiazole benzene derivatives were tested for their Glo-I inhibitory activity. Results showed that these compounds bind Glo-I active sites competitively with strong potential to inhibit this enzyme with IC50 values in micro-molar concentration. Docking poses revealed that these compounds interact with the zinc atom at the bottom of the active site, which plays an essential role in its viability.


Asunto(s)
Acetanilidas/farmacología , Inhibidores Enzimáticos/farmacología , Lactoilglutatión Liasa/antagonistas & inhibidores , Acetanilidas/química , Sitios de Unión , Inhibidores Enzimáticos/química , Humanos , Enlace de Hidrógeno , Lactoilglutatión Liasa/química , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Estructura Molecular , Unión Proteica , Relación Estructura-Actividad
3.
Oral Oncol ; 110: 104900, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32702630

RESUMEN

BACKGROUND: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. PATIENTS AND METHODS: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.


Asunto(s)
Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Terapia Molecular Dirigida , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Carcinoma de Células Escamosas de Cabeza y Cuello/mortalidad , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Inhibidores de Puntos de Control Inmunológico/farmacología , Proteínas de Punto de Control Inmunitario/genética , Proteínas de Punto de Control Inmunitario/metabolismo , Masculino , Persona de Mediana Edad , Terapia Molecular Dirigida/efectos adversos , Terapia Molecular Dirigida/métodos , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Carcinoma de Células Escamosas de Cabeza y Cuello/diagnóstico , Carcinoma de Células Escamosas de Cabeza y Cuello/etiología , Tasa de Supervivencia , Resultado del Tratamiento
4.
Drug Des Devel Ther ; 10: 3653-3660, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27877017

RESUMEN

Several applications of chalcones and their derivatives encouraged researchers to increase their synthesis as an alternative for the treatment of pathogenic bacterial and fungal infections. In the present study, chalcone derivatives were synthesized through cross aldol condensation reaction between 4-(N,N-dimethylamino)benzaldehyde and multiarm aromatic ketones. The multiarm aromatic ketones were synthesized through nucleophilic substitution reaction between 4-hydroxy acetophenone and benzyl bromides. The benzyl bromides, multiarm aromatic ketones, and corresponding chalcone derivatives were evaluated for their activities against eleven clinical pathogenic Gram-positive, Gram-negative bacteria, and three pathogenic fungi by the disk diffusion method. The minimum inhibitory concentration was determined by the microbroth dilution technique. The results of the present study demonstrated that benzyl bromide derivatives have strong antibacterial and antifungal properties as compared to synthetic chalcone derivatives and ketones. Benzyl bromides (1a and 1c) showed high ester activity against Gram-positive bacteria and fungi but moderate activity against Gram-negative bacteria. Therefore, these compounds may be considered as good antibacterial and antifungal drug discovery. However, substituted ketones (2a-b) as well as chalcone derivatives (3a-c) showed no activity against all the tested strains except for ketone (2c), which showed moderate activity against Candida albicans.


Asunto(s)
Antibacterianos/farmacología , Antifúngicos/farmacología , Bacterias/efectos de los fármacos , Benzaldehídos/química , Compuestos de Bencilo/farmacología , Candida albicans/efectos de los fármacos , Chalconas/química , Chalconas/farmacología , Bacterias Gramnegativas/química , Bacterias Grampositivas/química , Cetonas/química , Antibacterianos/química , Antifúngicos/química , Compuestos de Bencilo/química , Chalconas/síntesis química , Pruebas de Sensibilidad Microbiana , Relación Estructura-Actividad
5.
Eur J Obstet Gynecol Reprod Biol ; 68(1-2): 129-35, 1996 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8886695

RESUMEN

OBJECTIVE: A new concept is put forward to explain stress urinary incontinence (SUI). Urine continence depends on an intact strong internal sphincter and a reactive sympathetic activity. STUDY DESIGN: Thirty patients suffering from SUI were evaluated clinically and by urodynamic studies. During surgical repair of SUI, minute tissues were taken from the bladder neck and were examined microscopically after preparation and staining. Furthermore, examination of 15 postmortem specimens was done. Also a clinical trial was done to demonstrate the effects of sympathomimetics and alpha-blockers on the internal sphincter. RESULTS: There is paucity and dispersion of collagenous and elastic tissues constituents of the internal sphincter in patients suffering SUI. alpha-Blockers lower the urethral pressure, while sympathomimetics increases it. CONCLUSION: Sudden increase of intravesical pressure overcomes a weak internal sphincter leading to leakage of urine. This initiates a reactive sympathetic quick response that increases the internal sphincter tone preventing further leakage.


Asunto(s)
Incontinencia Urinaria de Esfuerzo/etiología , Antagonistas Adrenérgicos alfa/farmacología , Antagonistas Adrenérgicos alfa/uso terapéutico , Colágeno/análisis , Colágeno/fisiología , Tejido Elástico/patología , Tejido Elástico/fisiopatología , Femenino , Humanos , Norepinefrina/uso terapéutico , Fentolamina/uso terapéutico , Presión , Simpatomiméticos/farmacología , Simpatomiméticos/uso terapéutico , Uretra/efectos de los fármacos , Uretra/fisiopatología , Vejiga Urinaria/patología , Vejiga Urinaria/fisiopatología , Incontinencia Urinaria de Esfuerzo/patología , Incontinencia Urinaria de Esfuerzo/fisiopatología
6.
Int J Gynaecol Obstet ; 52(3): 291-2, 1996 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-8775690
7.
Microbios ; 93(374): 43-54, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9670554

RESUMEN

The antimicrobial potential of eight phenolic compounds isolated from olive cake was tested against the growth of Escherichia coli, Klebsiella pneumoniae, Bacillus cereus, Aspergillus flavus and Aspergillus parasiticus. The phenolic compounds included p-hydroxy benzoic, vanillic, caffeic, protocatechuic, syringic, and p-coumaric acids, oleuropein and quercetin. Caffeic and protocatechuic acids (0.3 mg/ml) inhibited the growth of E. coli and K. pneumoniae. The same compounds apart from syringic acid (0.5 mg/ml) completely inhibited the growth of B. cereus. Oleuropein, and p-hydroxy benzoic, vanillic and p-coumaric acids (0.4 mg/ml) completely inhibited the growth of E. coli, K. pneumoniae and B. cereus. Vanillic and caffeic acids (0.2 mg/ml) completely inhibited the growth and aflatoxin production by both A. flavus and A. parasiticus, whereas the complete inhibition of the moulds was attained with 0.3 mg/ml p-hydroxy benzoic, protocatechuic, syringic, and p-coumaric acids and quercetin.


Asunto(s)
Antiinfecciosos/farmacología , Aspergillus/efectos de los fármacos , Bacterias/efectos de los fármacos , Frutas/química , Fenoles/farmacología , Aflatoxina B1/biosíntesis , Antibacterianos , Antifúngicos/farmacología , Antioxidantes/farmacología , Aspergillus/crecimiento & desarrollo , Aspergillus/metabolismo , Aspergillus flavus/efectos de los fármacos , Aspergillus flavus/crecimiento & desarrollo , Aspergillus flavus/metabolismo , Bacillus cereus/efectos de los fármacos , Bacillus cereus/crecimiento & desarrollo , Bacterias/crecimiento & desarrollo , Ácidos Cafeicos/farmacología , Cromatografía Líquida de Alta Presión , Ácidos Cumáricos/farmacología , Escherichia coli/efectos de los fármacos , Escherichia coli/crecimiento & desarrollo , Ácido Gálico/análogos & derivados , Ácido Gálico/farmacología , Hidroxibenzoatos/farmacología , Glucósidos Iridoides , Iridoides , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/crecimiento & desarrollo , Parabenos/farmacología , Propionatos , Piranos/farmacología , Quercetina/farmacología , Ácido Vanílico/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA